ADENOVIRUS/ALFAVIRUS HYBRID VECTOR FOR EFFECTIVE ADMINISTRATION AND EXPRESSION OF THERAPEUTIC GENES IN TUMOR CELLS Russian patent published in 2010 - IPC C12N15/861 A61K48/00 

FIELD: medicine.

SUBSTANCE: adenoviral hybrid vector contains the first chain of adenovirus containing sequence of the first inverted terminal repeat (ITR) and signal sequence for packaging of adenovirus, the first non-coding sequence of the filler; sequence corresponding to tissue-specific promoter; chain of cDNA derived from alphavirus, which sequence is partially complementary to alphavirus RNA, including encoding sequence, an exogenous gene under interest; polyadenylation sequence and sequence of the second inverted terminal repeat (ITR). Pharmaceutical compositions containing such adenoviral vector hybrid and their application are revealed as well. The declared group of inventions can be used in the method of transfer of genetic material into cell, in particular into tumor cell which preferably expresses alpha-fetoprotein (AFP), and its application for induction of immune response against foreign antigens.

EFFECT: increasing of efficiency of therapeutic genes administration.

38 cl, 17 dwg